Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2020

View Archived Issues

Macrophage crosstalk inflames fat

PTC Therapeutics begins first-in-human study of PTC-857 for GBA Parkinson's disease

BioTheryX describes Protein Homeostatic Modulators with BTX-1188 showing notable antitumor activity

Novel inhibitor of CBP/p300 shows promising activity in AR-positive breast cancer

KIFC1 as a new therapeutic target and biomarker in CRC

Janpix and University of Toronto patent STAT3 and/or STAT5 inhibitors

Chinese investigators identify new ER antagonists

Shenzhen Targetrx Biotechnology divulges new protein kinase inhibitors

Camphor Pharmaceuticals synthesizes CDK4 and/or CDK6 inhibitors

Janssen Pharmaceutica and Johnson & Johnson present new HBV antivirals

Phase III FIDELIO-DKD study of finerenone meets primary endpoint

Sorrento Therapeutics presents preclinical data on STI-6129 for multiple myeloma

Pan-TRK/ROS1 dual inhibitor XZP-5955 shows brain penetration, activity against mutations

FDA clears IND Application for phase I study of FT-819

Kitov initiates phase I/II study of NT-219 in advanced cancers

Liver protein improves brain function after exercise

Kymera and Sanofi partner on IRAK4 protein degraders in inflammation and immunology

ProteinQure and AstraZeneca collaborate on peptide therapeutic design

Newave begins phase I study of LP-108 in relapsed or refractory MDS, CMML or AML

Blade developing BLD-0409 in phase I for chronic liver diseases

Ziopharm's CD19-specific CAR T therapy studied in new phase I trial

Quadriga opens enrollment in phase I study of QBS-10072S in cancers with high LAT1 expression

SAR-442085 preclinical data supports its further development

Uppsala University researchers describe new urothelial bladder cancer model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...